1Misaghian N, Ligresti G, Steelman l_S, et al. Target- ing the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia, 2009, 23: 25-42.
2Bonardi F, Fusetti F, Deelen P, et al. A proteo- mics and transcriptomics approach to identify leukemic stem cell (LSC) markers. Mol Cell Pro- teomies, 2013, 12 (3): 626-637.
3Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastie leukemia. Cancer Res, 2011, 71 (4): 1374-1384.
4Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phago- cytosis and eradicate non-Hodgkin ymphoma. Cell,2010, 142 (5): 699-713.
5Chakraborty S, Stark JM, Sun CL, et al. Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeat- ed breakage-fusion-bridge cycles mediated by in- creased nonhomologous end joining. Blood, 2012, 119 (26): 6187-6197.
6Majeti R. Monoclonal antibody therapy directed a- gainst human acute myeloid leukemia stem ceils. Oncogene, 2011, 30 (9): 1009-1019.
7Tettamanti S, Matin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol, 2013, 161 (3): 389-401.
8Pang WW, Pluvinage JV, Price EA, et al. Hem- atopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A, 2013, 110 (8): 3011-3016.
9Gerber JM, Smith BD, Ngwang B, et al. A clinical- ly relevant population of leukemic CD34 (+)CD38 (-) cells in acute myeloid leukemia. Blood, 2012, 119 (15): 3571-3577.
10Irandoust M, Alvarez Zarate J, Hubeek I, et al. Engagement of SIRPct inhibits growth and induces programmed cell death in acute myeloid leukemia cells. PLoS One, 2013, 8 (1): e52143.
